{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T16:37:10Z","timestamp":1787071030951,"version":"build-2736575974"},"reference-count":36,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,4]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose:<\/jats:title>\n                    <jats:p>\n                      The chronic myeloid leukemia (CML) is characterized by the presence of t(9;22)(q34;q11) that results in chimerization of\n                      <jats:italic toggle=\"yes\">BCR<\/jats:italic>\n                      and\n                      <jats:italic toggle=\"yes\">ABL<\/jats:italic>\n                      genes on the rearranged chromosome 22 or Philadelphia chromosome (Ph). Imatinib has been established as the first line of therapy for CML; in case of Imatinib failure or resistance, other second or third generation tyrosine kinase inhibitors (TKIs) are considered. However, acquisition of additional clonal abnormalities (ACAs) interferes in management of CML. We described a complex scenario of cytogenetic remission, relapse, response to TKIs and behavior of ACAs in a case of CML.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and Methods:<\/jats:title>\n                    <jats:p>\n                      Conventional G-banding and FISH cytogenetics, and quantitative PCR studies were conducted in the bone marrow for diagnosis and follow up (FU) of the changes of\n                      <jats:italic toggle=\"yes\">BCR-ABL<\/jats:italic>\n                      gene and ACAs at different time intervals.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Ph\u2212 chromosome disappeared within 6 months of Imatinib therapy, and re-appeared within a year. Subsequent change of TKI to dasatinib eliminated the Ph+ clone, but established an ACA with trisomy 8 (+8). Further change to Nilotinib, eliminated +8 clone, but re-emergence of Ph+ clone occurred with an ACA with monosomy 7 (\u22127). Reinstate of Dasatinib eliminated Ph+ and \u22127 clones, but with gradual reappearance of Ph+ and +8 clones. The patient discontinued FU, though participated in a long term examination.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>The complexity of ACAs and Ph+ clones needs frequent monitoring with changes of TKI and technologies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/jcrt.jcrt_1755_20","type":"journal-article","created":{"date-parts":[[2022,7,26]],"date-time":"2022-07-26T04:10:27Z","timestamp":1658808627000},"page":"760-764","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":4,"title":["Effects of tyrosine kinase inhibitors for controlling Ph+ clone and additional clonal abnormalities in a chronic myeloid leukemia"],"prefix":"10.4103","volume":"18","author":[{"given":"Bani Bandana","family":"Ganguly","sequence":"first","affiliation":[{"name":"MGM Center for Genetic Research and Diagnosis, MGM New Bombay Hospital, Kolkata, India"},{"name":"MGM Center for Genetic Research and Diagnosis, MGM Institute of Health Sciences, Navi Mumbai, Maharashtra, Kolkata, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shouvik","family":"Mandal","sequence":"additional","affiliation":[{"name":"MGM Center for Genetic Research and Diagnosis, MGM New Bombay Hospital, Kolkata, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debasis","family":"Banerjee","sequence":"additional","affiliation":[{"name":"MGM Center for Genetic Research and Diagnosis, MGM Institute of Health Sciences, Navi Mumbai, Maharashtra, Kolkata, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nitin N.","family":"Kadam","sequence":"additional","affiliation":[{"name":"MGM Center for Genetic Research and Diagnosis, MGM Institute of Health Sciences, Navi Mumbai, Maharashtra, Kolkata, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2022,7,25]]},"reference":[{"key":"R1-20250514","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/243290a0","article-title":"Letter: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and giemsa staining","volume":"243","author":"Rowley","year":"1973","journal-title":"Nature"},{"key":"R2-20250514","doi-asserted-by":"crossref","first-page":"124","DOI":"10.4103\/0973-1482.34695","article-title":"Conventional and fluorescence in situ hybridization analysis of three-way complex BCR-ABL rearrangement in a chronic myeloid leukemia patient","volume":"3","author":"Ganguly","year":"2007","journal-title":"J Cancer Res Ther"},{"key":"R3-20250514","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1007\/s13238-010-0016-z","article-title":"Molecular and cellular bases of chronic myeloid leukemia","volume":"1","author":"Chen","year":"2010","journal-title":"Protein Cell"},{"key":"R4-20250514","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1172\/JCI9083","article-title":"Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia","volume":"105","author":"Druker","year":"2000","journal-title":"J Clin Invest"},{"key":"R5-20250514","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S1535-6108(02)00039-9","article-title":"Smart drugs: Tyrosine kinase inhibitors in cancer therapy","volume":"1","author":"Shawver","year":"2002","journal-title":"Cancer Cell"},{"key":"R6-20250514","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1182\/blood.V114.22.1126.1126","article-title":"International randomized study of interferon vs. STI571 (IRIS) 8-year follow up: Sustained survival and low risk for progression or events in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib","volume":"114","author":"Deininger","year":"2009","journal-title":"Blood"},{"key":"R7-20250514","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1016\/S1470-2045(07)70342-X","article-title":"Part 1: Mechanisms of resistance to imatinib in chronic myeloid leukemia","volume":"8","author":"Apperley","year":"2007","journal-title":"Lancet Oncol"},{"key":"R8-20250514","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1200\/JCO.2010.32.0598","article-title":"Tolerability-adapted imatinib 800 mg\/d versus 400 mg\/d versus 400 mg\/d plus interferon-\u03b1 in newly diagnosed chronic myeloid leukemia","volume":"29","author":"Hehlmann","year":"2011","journal-title":"J Clin Oncol"},{"key":"R9-20250514","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/s13237-019-00271-6","article-title":"Genetics and tyrosine kinase inhibitors of chronic myeloid leukemia","volume":"62","author":"Ganguly","year":"2019","journal-title":"Nucleus"},{"key":"R10-20250514","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1002\/gcc.20611","article-title":"Cryptic and partial deletions of PRDM16 and RUNX1 without t (1;21)(p36;q22) and\/or RUNX1-PRDM16 fusion in a case of progressive chronic myeloid leukemia: A complex chromosomal rearrangement of underestimated frequency in disease progression?","volume":"47","author":"Deluche","year":"2008","journal-title":"Genes Chromosomes Cancer"},{"key":"R11-20250514","doi-asserted-by":"crossref","first-page":"2254","DOI":"10.1172\/JCI41246","article-title":"Chronic myeloid leukemia: Mechanisms of blastic transformation","volume":"120","author":"Perrotti","year":"2010","journal-title":"J Clin Invest"},{"key":"R12-20250514","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s11899-012-0114-5","article-title":"Genetic mechanisms of chronic myeloid leukemia blastic transformation","volume":"7","author":"Skorski","year":"2012","journal-title":"Curr Hematol Malig Rep"},{"key":"R13-20250514","doi-asserted-by":"crossref","first-page":"470","DOI":"10.5581\/1516-8484.20110124","article-title":"Imatinib resistance: A review of alternative inhibitors in chronic myeloid leukemia","volume":"33","author":"Bitencourt","year":"2011","journal-title":"Rev Bras Hematol Hemoter"},{"key":"R14-20250514","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.canlet.2011.08.009","article-title":"Rapid automated detection of ABL kinase domain mutations in imatinib-resistant patients","volume":"312","author":"Tanaka","year":"2011","journal-title":"Cancer Lett"},{"key":"R15-20250514","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1080\/10428190701713689","article-title":"Src-family kinases in the development and therapy of Philadelphia chromosome-positive chronic myeloid leukemia and acute lymphoblastic leukemia","volume":"49","author":"Li","year":"2008","journal-title":"Leuk Lymphoma"},{"key":"R16-20250514","doi-asserted-by":"crossref","first-page":"2742","DOI":"10.1182\/blood-2016-01-690230","article-title":"Risk stratification of chromosomal abnormalities in chronic myelogenous leukemia in the era of tyrosine kinase inhibitor therapy","volume":"127","author":"Wang","year":"2016","journal-title":"Blood"},{"key":"R17-20250514","doi-asserted-by":"crossref","first-page":"2303","DOI":"10.1182\/blood-2006-09-047266","article-title":"Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy","volume":"109","author":"Hochhaus","year":"2007","journal-title":"Blood"},{"key":"R18-20250514","doi-asserted-by":"crossref","first-page":"506","DOI":"10.3109\/02841861003660031","article-title":"Influence of complex variant chromosomal translocations in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors","volume":"49","author":"Stagno","year":"2010","journal-title":"Acta Oncol"},{"key":"R19-20250514","doi-asserted-by":"crossref","first-page":"2263","DOI":"10.1038\/leu.2015.96","article-title":"Impact of trisomy 8 on treatment response and survival of patients with chronic myelogenous leukemia in the era of tyrosine kinase inhibitors","volume":"29","author":"Wang","year":"2015","journal-title":"Leukemia"},{"key":"R20-20250514","doi-asserted-by":"crossref","first-page":"49","DOI":"10.5045\/br.2018.53.1.49","article-title":"Additional cytogenetic aberrations in chronic myeloid leukemia: A single-center experience in the Middle East","volume":"53","author":"Safaei","year":"2018","journal-title":"Blood Res"},{"key":"R21-20250514","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1002\/cncr.22936","article-title":"The prognosis for patients with chronic myeloid leukemia who have clonal cytogenetic abnormalities in Philadelphia chromosome-negative cells","volume":"110","author":"Deininger","year":"2007","journal-title":"Cancer"},{"key":"R22-20250514","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1182\/blood-2013-05-501569","article-title":"European LeukemiaNet recommendations for the management of chronic myeloid leukemia 2013","volume":"122","author":"Baccarani","year":"2013","journal-title":"Blood"},{"key":"R23-20250514","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1038\/leu.2016.6","article-title":"Differential impact of additional chromosomal abnormalities in myeloid vs. lymphoid blast phase of chronic myelogenous leukemia in the era of tyrosine kinase inhibitor therapy","volume":"30","author":"Chen","year":"2016","journal-title":"Leukemia"},{"key":"R24-20250514","doi-asserted-by":"crossref","first-page":"6760","DOI":"10.1182\/blood-2011-08-373902","article-title":"Impact of additional cytogenetic aberrations at diagnosis on prognosis of CML: Long-term observation of 1151 patients from the randomized CML study IV","volume":"118","author":"Fabarius","year":"2011","journal-title":"Blood"},{"key":"R25-20250514","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1182\/blood-2011-10-384651","article-title":"Additional chromosomal abnormalities in Philadelphia-positive clone: Adverse prognostic influence on frontline imatinib therapy: A GIMEMA working party on CML analysis","volume":"120","author":"Luatti","year":"2012","journal-title":"Blood"},{"key":"R26-20250514","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1126\/science.289.5486.1938","article-title":"Structural mechanism for STI-571 inhibition of abelson tyrosine kinase","volume":"289","author":"Schindler","year":"2000","journal-title":"Science"},{"key":"R27-20250514","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1002\/ardp.19963290707","article-title":"Phenylamino-pyrimidine (PAP) derivatives: A new class of potent and selective inhibitors of protein kinase C (PKC)","volume":"329","author":"Zimmermann","year":"1996","journal-title":"Arch Pharm (Weinheim)"},{"key":"R28-20250514","doi-asserted-by":"crossref","first-page":"6658","DOI":"10.1021\/jm049486a","article-title":"Discoveryof N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino) thiazole-5-carboxamide (BMS-354825), a dualSrc\/Abl kinase inhibitor with potent antitumor activity in preclinical assays","volume":"47","author":"Lombardo","year":"2004","journal-title":"J Med Chem"},{"key":"R29-20250514","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1200\/JCO.2008.19.8853","article-title":"Activity of bosutinib, dasatinib, and nilotinib against 18 imatinib-resistant BCR\/ABL mutants","volume":"27","author":"Redaelli","year":"2009","journal-title":"J Clin Oncol"},{"key":"R30-20250514","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.ccr.2005.01.007","article-title":"Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl","volume":"7","author":"Weisberg","year":"2005","journal-title":"Cancer Cell"},{"key":"R31-20250514","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.critrevonc.2014.11.001","article-title":"Mechanisms of resistance to BCR-ABL TKIs and the therapeutic strategies: A review","volume":"93","author":"Yang","year":"2015","journal-title":"Crit Rev Oncol Hematol"},{"issue":"Suppl 1","key":"R32-20250514","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1053\/j.seminoncol.2011.01.016","article-title":"Nilotinib: A novel, selective tyrosine kinase inhibitor","volume":"38","author":"Blay","year":"2011","journal-title":"Semin Oncol"},{"key":"R33-20250514","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1038\/nrclinonc.2013.51","article-title":"Haematological cancer: Nilotinib reduces emergence of BCR-ABL mutations in CML","volume":"10","author":"Marchesi","year":"2013","journal-title":"Nat Rev Clin Oncol"},{"key":"R34-20250514","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1038\/leu.2011.323","article-title":"Nilotinib in patients with Ph+chronic myeloid leukemia in accelerated phase following imatinib resistance or intolerance: 24-month follow-up results","volume":"26","author":"le Coutre","year":"2012","journal-title":"Leukemia"},{"key":"R35-20250514","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.mrrev.2016.04.009","article-title":"Mutations of myelodysplastic syndromes (MDS): An update","volume":"769","author":"Ganguly","year":"2016","journal-title":"Mutat Res Rev Mutat Res"},{"key":"R36-20250514","doi-asserted-by":"crossref","first-page":"586","DOI":"10.2174\/1568009617666170330145002","article-title":"Small-molecule inhibitors of epigenetic mutations as compelling drugtargets for myelodysplastic syndromes","volume":"17","author":"Ganguly","year":"2017","journal-title":"Curr Cancer Drug Targets"}],"container-title":["Journal of Cancer Research and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/jcrt.JCRT_1755_20","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T15:40:33Z","timestamp":1787067633000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/jcrt.JCRT_1755_20"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4]]},"references-count":36,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.4103\/jcrt.jcrt_1755_20","relation":{},"ISSN":["0973-1482","1998-4138"],"issn-type":[{"value":"0973-1482","type":"print"},{"value":"1998-4138","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4]]},"assertion":[{"value":"2020-12-04","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-10-25","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}